New Clinical Trial: Optimal Methods of Disease Progression and Survival Analysis in Children and Adults Patients With Adrenocortical Cancer (ACC) (NCT04358107)
WHY IT MATTERS
This study is actively collecting data that could help doctors better predict outcomes and choose more effective treatments for ACC patients, though it is not currently recruiting new participants.
Researchers are studying 1,000 children and adults with adrenocortical carcinoma (ACC), a rare cancer of the adrenal glands. They want to understand why some people survive longer than others and whether certain treatments work better. The average person with ACC lives about 14.5 months after diagnosis, but survival times vary widely.
NCT ID: NCT04358107 Status: ACTIVE_NOT_RECRUITING Conditions: Adrenocortical Carcinoma Enrollment: 1000 Sponsor: National Cancer Institute (NCI) Summary: Background: Adrenocortical carcinoma (ACC) is a rare cancer. It has a poor prognosis. Some people live with ACC for years; others live for just months. The average survival from the time of diagnosis is 14.5 months. Researchers do not know if local directed treatments may work better than systemic ones. They want to learn more about ACC by looking at data from previous studies. Objective: To characterize the overall prognosis and treatment responses in people with ACC with various systemic th
ASK YOUR DOCTOR
Ask your oncologist if your ACC data might be included in this NCI study or if findings from this research could inform your treatment decisions.